In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Management of antithrombotic/antiplatelet therapy in patients with aortic stenosis undergoing transcatheter aortic valve replacement

Session Poster Session 2

Speaker Manuel Munoz-Garcia

Congress : Heart Failure 2019

  • Topic : cardiovascular pharmacology
  • Sub-topic : Cardiovascular Drug Therapy, Other
  • Session type : Poster Session
  • FP Number : P1181

Authors : M Munoz-Garcia (Malaga,ES), E Munoz-Garcia (Malaga,ES), A J Munoz Garcia (Malaga,ES), JM Garcia-Pinilla (Malaga,ES), L Morcillo-Hidalgo (Malaga,ES), A Robles Mezcua (Malaga,ES), JH Alonso-Briales (Malaga,ES), JM Hernandez-Garcia (Malaga,ES), MF Jimenez-Navarro (Malaga,ES), JJ Gomez-Doblas (Malaga,ES)

M Munoz-Garcia1 , E Munoz-Garcia1 , A J Munoz Garcia1 , JM Garcia-Pinilla1 , L Morcillo-Hidalgo1 , A Robles Mezcua1 , JH Alonso-Briales1 , JM Hernandez-Garcia1 , MF Jimenez-Navarro1 , JJ Gomez-Doblas1 , 1University Hospital Virgen de la Victoria, Department of Cardiology - Malaga - Spain ,


Background: Many cardiac patients undergoing transcatheter aortic valve implantation (TAVI) required combined antithrombotic therapy consisting of an anticoagulant and inhibition of platelet function. Currently the optimal combination of anticoagulants and anti-platelet therapy is unknown, but it is well established that the combination increased bleeding rates.
The aim of this study was to analyze prevalence ischaemic and bleeding events in patients undergoing TAVI in according to management of antithrombotic therapy
Methods: A total of 637 consecutive patients with aortic stenosis undergoing TAVI were evaluated, between April 2008 and December 201, on base to antithrombotic/antiplatelet therapy received at discharge.
Results: The patients were characterized by had a HAS-BLED score 2.8± 1.1, CHADS2 3.35±1.0 and CHAD2-Vasc score 5.08±1.2. In 53 patiens  (8.3%) were treated in monotherapy with an antiplatelet, dual antiplatelet in 424 (60.6%),  (3.2%) triple therapy in 29 patients (4.6%) and  131 patients (20.6%) with oral anticoagulant plus a thienopyridine.  We  found not differences  in mortality in according to antithrombotic therapy, respectively: 52.9% vs. 37.4% vs. 34.5% vs 47, [HR= 1.087 (95% CI 0.912-1.297), p=0.350], There were no differences in stroke 15.1% vs. 7.3% vs. 13.8% vs 10%, [HR=1.029 (95% CI 0.767-1.392), p=0.854], major bleeding 5.7% vs. 3.8% vs. 3.4% vs. 6.1% %, [HR=1.167 (95% CI 0.782-1.741), p=0.449], and myocardial infarction 1.9% vs. 3.8% vs. 3.4% vs. 0.8%, %, [HR=0.669 (95% CI 0.366-1.225), p=0.193].
Conclusions: in this study  there was no differences in rate of mortality or isquemic and hemorragic events, although there were trend to higher rate of mortality in patients with only antiplatelet and anticoagulant plus thienopyridine.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are